Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ: VIR )

7.380 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
From Vir Biotechnology, Inc.
Via Business Wire
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT normalization rates with tobevibart and elebsiran. 
Via Benzinga
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Evaluating Vir Biotechnology: Insights From 5 Financial Analysts
Via Benzinga
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
Via Benzinga
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
Via Benzinga
Recap: Vir Biotechnology Q4 Earnings
Via Benzinga
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
From Vir Biotechnology, Inc.
Via Business Wire
Earnings Outlook For Vir Biotechnology
Via Benzinga
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
From Vir Biotechnology, Inc.
Via Business Wire
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
From Vir Biotechnology, Inc.
Via Business Wire
VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024
VIR stock results show that Vir Biotechnology beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
From Vir Biotechnology, Inc.
Via Business Wire
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations. 
Via InvestorPlace
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses. 
Via InvestorPlace
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
From Vir Biotechnology, Inc.
Via Business Wire
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings. 
Via InvestorPlace
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
From Vir Biotechnology, Inc.
Via Business Wire
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results. 
Via Benzinga
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
From Vir Biotechnology, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.